GE Healthcare (GEHC) is expected to announce a USD 945mln cash purchase of Sofie, a manufacturer of radioactive substances used in medical-imaging procedures, reports WSJ

Bolt-on acquisitions of radiopharmaceutical suppliers by imaging-equipment makers fit an established pattern in the sector, where diagnostics companies have been paying up for scarce production and distribution capacity in isotopes as demand for targeted tracers has grown faster than supply. Deals of this size are typically funded from balance-sheet cash and are rarely thesis-changing for the acquirer on announcement; the established pattern is a modest positive or neutral reaction in the buyer, with the more durable read-through being vertical integration of the supply chain rather than near-term earnings accretion. The distinction worth drawing is between announced intent and a signed agreement: reports sourced ahead of confirmation have on previous occasions shifted on price, structure, or timing, and leak-driven reports occasionally draw competing bidders into the open. GEHC's prior form since its separation from the parent has been disciplined, smaller-scale tuck-ins rather than transformational deals, so this sits within its stated capital-allocation frame. Worth watching are formal confirmation, the funding mix, any disclosed multiple, and whether peers in imaging or radiopharma respond with their own consolidation moves, as serial dealmaking in this niche has historically come in clusters.